Solutia Reports Third Quarter 20...(70 -- 1600 Net chan...)

Date:10/26/2009

70 -- 1,600 Net change in long-term revolving credit facilities (181) (3) 190 Proceeds from stock issuances 119 422 250 Proceeds from short-term debt obligations 22 -- -- Payment of short-term debt obligations (15) -- (966) Payment of long-term debt obligations (83) (434) (366) Payment of debt obligations subject to compromise -- -- (221) Debt issuance costs (4) (1) (136) Purchase of treasury shares (2) -- -- Other, net (5) (2) -- --- --- Cash Provided by (Used in) Financing Activities (92) 10 351 ---- -- --- INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 79 (45) (90) CASH AND CASH EQUIVALENTS: Beginning of period 32 83 173 --- --- --- End of period $111 $38 $83 ==== === === SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash payments for interest $83 $85 $43 Cash payments for income taxes, net of refunds 9 15 4

Notes to Editor: Saflex and CPFilms are registered trademarks of Solutia Inc. and/or its subsidiaries.

Important Information Regarding Outlook

There is no guarant
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009